• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    20 Years: A Discussion on the Past & Future of Medical Product Outsourcing

    A Combined Effort for Drug Delivery & Combo Product Technology

    Examining Medical Packaging & Sterilization on Multiple Fronts

    Medical Molding Modernized

    Computer Concepts for Medical Device Design
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Olympus Releases Next-Gen ESG-410 Electrosurgical Generator

    NICO Corporation Touts Positive ENRICH Trial Results

    Study Reveals Graphene-Based Biosensors' Potential in Detecting Critical Biomarker

    Obvius Robotics Completes First-in-Human Cases

    Gore Begins Enrollment for VIAFORT Vascular Stent Iliofemoral Study
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    20 Years: A Discussion on the Past & Future of Medical Product Outsourcing

    A Combined Effort for Drug Delivery & Combo Product Technology

    Examining Medical Packaging & Sterilization on Multiple Fronts

    Medical Molding Modernized

    Computer Concepts for Medical Device Design
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Elizabeth Holmes’ Pre-Prison Public Persona

    Trending in Healthcare Dealmaking: Creativity, Diversification, and Distress

    How Human Factors Engineering Can Contribute to Medical Device Packaging

    How Companies Can Create a Unique Selling Proposition

    Updating Medical Device Software in the Field
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Providence Enterprise USA Inc.

    Medbio LLC

    LEMO USA Inc.

    Halkey-Roberts Corporation

    NDH Medical Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How the CHIPS Act and R&D Tax Credits Will Shape the Medtech Manufacturing Landscape

    Solving the Skills Gap Stalling the March of UK Life Sciences

    5 Ways to Reduce Nearshoring & Reshoring Costs Using Automation

    The Future of Hearing Aids: xMEMS Develops All-Silicon, Solid-State Micro Speaker

    Navigating Chinese Regulatory Requirements for Medical Device Localization
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Providence Enterprise USA Inc.

    Medbio LLC

    LEMO USA Inc.

    Halkey-Roberts Corporation

    NDH Medical Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    The Complex Regulatory Pathway for Medical Devices and Drug Delivery Systems

    Submitting combination products for regulatory review can be complex and confusing.

    The Complex Regulatory Pathway for Medical Devices and Drug Delivery Systems
    Image courtesy of WuXi AppTec Medical Device Testing.
    Kim Ehman, WuXi AppTec Medical Device Testing07.19.22
    Submitting combination products for regulatory review can be complex and confusing. According to the U.S. Food and Drug Administration (FDA), a combination product is composed of any mixture of drug, device, or biological product. Combination products fall into three distinct categories:

    • Single-entity products consist of two or more regulated components that are physically, chemically, or otherwise combined and produced as a single entity. Drug-eluting stents, transdermal patches, EpiPens, and metered dose inhalers are all single-entity products.
    • Co-packaged products consist of two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products. Drugs or vaccines packaged with a syringe, surgical trays with instruments, and first aid kits containing bandages, gauze, antibiotics, and ointments are considered co-packaged.
    • Cross-labeled products are drugs, devices, or biologics packaged separately but, according to their labeling, are intended for use only with another approved drug, device, or biological product. Combinations of investigational drugs, devices, or biological products also qualify here. A photosensitizing drug with an activating laser/light source would be considered cross-labeled.  

    The regulatory submission process most commonly drives confusion about combination products. Determining which FDA center will review a combination product submission depends on several factors, including device type, its primary mode of action (PMOA), and geographic market. For a combination product, the PMOA is the single mode of action that provides the most important therapeutic action. Navigating multiple submission paths and regulatory fluidity can be challenging, but manufacturers and drug sponsors can take steps to strengthen submissions, shorten timelines, improve testing outcomes, and support patient safety.

    Determining the Primary Reviewer

    The FDA's Office of Combination Products (OCP) classifies medical products as devices, drugs, biologics, or combination products, and assigns them to review centers. The OCP also serves as the primary point of contact between the agency and industry. A product's PMOA determines which regulatory center has primary jurisdiction and will ultimately serve as the lead reviewer.

    • Device-led products: Products whose PMOA is dependent on a device will submit to the Center for Devices and Radiological Health (CDRH), which oversees medical devices and safe radiation-emitting products. A drug-eluting stent, for example, is a CDRH-regulated device. The stent keeps the artery open, which is the device's primary function. The drug plays a vital role in preventing blood clots and mitigating side effects like irritation or inflammation, but the product’s most important therapeutic action is the stent, not the drug.
    • Drug-led products: Products whose PMOA is dependent on a drug will submit to the Center for Drug Evaluation and Research (CDER), which oversees prescription, over-the-counter and generic drugs. This includes medication, fluoride toothpaste, antiperspirants, dandruff shampoo, and sunscreen. An EpiPen is a CDER-regulated device, as the drug constricts blood vessels, increases blood pressure, and decreases the swelling from allergic reactions. The injector administers medication, but epinephrine is the life-saving drug that prevents anaphylaxis.
    • Biologic-led products: Products whose PMOA depends on biologics and related products (i.e., vaccines, live biotherapeutics, blood products) will submit to the Center for Biologics Evaluation and Research (CBER), which oversees medical devices used for cellular/gene therapies, tissue products and blood collection, screening, and processing. An anticoagulant is a CBER-regulated device because it is a biologic that helps prevent blood clots and reduces the chances of strokes and heart attacks.

    When a device has two independent modes of action, and neither is subordinate to the other, the FDA uses an algorithm for determining center assignment. Manufacturers or drug sponsors that disagree with their product classification or its PMOA can submit a formal request for designation (RFD)—essentially asking the OCP to reconsider their product's classification or center assignment. There is also an informal, nonbinding version called a pre-RFD. In either case, manufacturers or sponsors can propose a change to their center assignment, leaving the OCP to make the final, formal determination. If the OCP does not provide feedback on the RFD within 60 days, the manufacturer/sponsor's proposed center assignment makes the final determination.

    Each review center determines product classification, but preclinical safety testing for combination products is not fully defined in FDA documentation. This may require manufacturers or sponsors to adjust their approach and embrace outside-the-box thinking. Knowing reviewers' expectations can help manufacturers and sponsors prepare safety data and supporting information that will help them achieve regulatory success.

    Biological Evaluations of Combination Product

    A complete biological evaluation should identify a product’s biocompatibility. The International Organization for Standardization (ISO) published a revision to 10993-18 in 2020 and is scheduled to revise 10993-17 this year. Together, the two standards provide approaches for robustly evaluating devices in order to characterize potential risks, and directly impact combination products.

    But standards can change so quickly that even recent biological safety evaluations may be outdated. In fact, the FDA published new premarket guidance for combination products in January this year. Clearly, fully supporting patient safety in combination products requires a comprehensive strategy. This includes chemical characterization, a toxicological risk assessment (TRA), and biocompatibility testing.

    In drug-device or biologic-device combination products, the drug or biologic substance should be fully characterized (chemistry, mechanisms of action, safety profile), and the final product (drug- or biologic-device product) also needs to be characterized, which includes a complete biocompatibility and chemistry evaluation. Biocompatibility and chemical characterization studies can become complex, as some tests may be conducted with and without the drug or biologic (to demonstrate the drug or biologic’s potential impact on the device and vice versa). Thus, before initiating biocompatibility or chemical characterization studies, a test plan should be developed to determine which tests are applicable to the device only or to the final finished product.

    Biocompatibility testing can address various potential hazards, including sensitization, irritation, and general toxicity; however, biocompatibility testing alone may not always sufficiently assess safety. Consistent with ISO 10993-1 (2018), chemical characterization testing (extractables and leachables testing), followed by a toxicological risk assessment (TRA) may address many biocompatibility endpoints, saving manufacturers both time and money. When a chemical characterization study is conducted properly, the TRA can address several biocompatibility endpoints, including short- and long-term toxicity risks, genotoxicity and carcinogenicity potential, as well as developmental and reproductive toxicity. This is done by evaluating each identified compound in the chemical characterization study and comparing an acceptable level to the estimated patient exposure.

    Revised regulations and rigorous chemical and toxicological analyses mean toxicologists will likely find "equivocal" results—those for which there is insufficient data to support the TRA. This should not cause panic. When toxicologists find equivocal results, they can conduct targeted analyses and simulated-use studies to help mitigate risk and further demonstrate product safety.

    Partnering With Experts

    Combination products are complex, and the regulatory process can be arduous. Manufacturers should be prepared for a lengthier timeline than they are used to, given the level to which the drug, device, biologic, production, and packaging environments will be analyzed. The expertise, equipment, and database needed to comply with evolving ISO standards can present additional challenges. But manufacturers and sponsors do not have to face these hurdles alone.

    When teams lack in-house expertise, collaborating with partners that have deep technical and regulatory experience can be invaluable. Reliable laboratory testing partners fill in where internal expertise is limited and collaborate to develop the strongest possible submission.

    Laboratory partners can also provide a bridge between manufacturers and regulators. Some lab partners have staff that serves on regulatory boards and have unique insight into evolving guidance and information. Another advantage to working with technical partners is their guidance during and after pre-submission meetings with the FDA.

    Pre-submission meetings are informal touchpoints with the agency that provide opportunities to discuss a device or drug delivery system and gather feedback. Regulators can answer outstanding questions and confirm submission expectations that might impact a product's biological evaluation. The meetings are usually limited to an hour per device, but they can provide critical information early enough for manufacturers to make fundamental decisions about the path forward. Lab testing partners can also partake in pre-submission meetings to provide valuable counsel to manufacturers and sponsors.

    Pre-submission meetings are available for every product, and the FDA recommends manufacturers and sponsors take advantage of them. However, cross-labeled combination products raise distinct considerations. Cross-labeled products often involve filing a new drug application for the drug and premarket notification 510(k) for the device. Despite filing separate submissions, manufacturers and sponsors should continue using their originally dedicated review center for all correspondence. The original review center is responsible for ensuring that representatives from the necessary centers, including the OCP, have conducted premarket product reviews and will attend pre-submission meetings.

    Once manufacturers and sponsors understand their device's category and submission pathway, they can tailor their study design to fit their reviewer's requirements. This is another area in which a trusted laboratory testing partner can provide great value.

    The complexity of combination product submissions magnifies the importance of correct study design. Multiple centers will request varying endpoints, specific regulatory standards will apply to certain products, and reams of documentation will be used to justify the product's analytical approach. This information should be contained in a drug master file (DMF). DMFs provide confidential, detailed information about facilities, processes, or articles used to manufacture, process, package, and store human drug products. Lab testing partners can ensure efficient and thorough information gathering, organizing and sharing.

    A Final Word

    Understanding the regulatory journey for medical devices and drug delivery systems can be intimidating. Regulatory standards continuously evolve, rendering recent submission data obsolete and intensifying or changing the analytical approach. Determining which FDA center will review a combination product—and delivering the requisite data—is another aspect that may require a bit of guidance. Additionally, regulators now expect detailed chemical and toxicological data.

    Despite this, device manufacturers and drug sponsors should not feel alone in the submission process. Testing partners offering advanced equipment, impeccable credentials, and firsthand knowledge of the regulatory landscape can provide peace of mind and deliver regulatory success. 


    Dr. Kim Ehman, Ph.D., DABT, is technical director of Regulatory Toxicology, with a focus on medical device and combination products. Dr. Ehman has more than 18 years of toxicology and medical device experience, with expertise in toxicological risk assessments for medical devices, food and beverage products, and electronic nicotine delivery systems. Before joining WuXi AppTec Medical Device Testing, she worked as a toxicologist for RTI International, Toxicology Regulatory Services, and Altria Client Services. She earned her Ph.D. in parasitology from McGill University and conducted postdoctoral research at the U.S. EPA in developmental neurotoxicology. In her current position, Dr. Ehman provides medical device manufacturers and suppliers with technical and regulatory support for biocompatibility test programs and conducts quantitative toxicological risk assessments to support product safety and risk management decisions. She earned a B.Sc. degree in biology from Seton Hall University.
    Related Searches
    • Testing
    Related Knowledge Center
    • Testing
      Loading, Please Wait..

      Trending
      • Olympus To Establish Digital Excellence Centers
      • A New Approach To Post-Market Surveillance
      • Philips Names New Supervisory Board Chairman
      • Healthcare Changes Prompt Medtronic To Merge Sales Force Medtronic, Inc. Is Combining Its U.S. Ca
      • Labcorp's Clinical Development Spinoff To Be Called Fortrea
      Breaking News
      • Olympus Releases Next-Gen ESG-410 Electrosurgical Generator
      • NICO Corporation Touts Positive ENRICH Trial Results
      • Study Reveals Graphene-Based Biosensors' Potential in Detecting Critical Biomarker
      • Obvius Robotics Completes First-in-Human Cases
      • Gore Begins Enrollment for VIAFORT Vascular Stent Iliofemoral Study
      View Breaking News >
      CURRENT ISSUE

      June 2023

      • 20 Years: A Discussion on the Past & Future of Medical Product Outsourcing
      • A Combined Effort for Drug Delivery & Combo Product Technology
      • Examining Medical Packaging & Sterilization on Multiple Fronts
      • Medical Molding Modernized
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Reproductive Factors, Menopause Play Understated Role in Heart Health Risk
      Verdure Sciences Earns NSF/ANSI 455-2 Dietary Supplement GMP Certification
      Sempera Organics and Alkemist Labs Announce Partnership for Mushroom Testing
      Coatings World

      Latest Breaking News From Coatings World

      Sandrine Garnier Joins ChemQuest as a Director
      Greenbuild Announces 2023 Keynote Speaker
      PPG’s New Paint for a New Start Initiative to Beautify Schools Worldwide with Colorful Makeovers
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Olympus Releases Next-Gen ESG-410 Electrosurgical Generator
      NICO Corporation Touts Positive ENRICH Trial Results
      Study Reveals Graphene-Based Biosensors' Potential in Detecting Critical Biomarker
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Qosina, Carolina Components Partner to Market Bioprocess Components
      Astellas, KateTx Enter Exclusive License Agreement to Develop KT430
      Telix Opens $21.2M European Radiopharmaceutical Production Facility
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Boots CFO Michael Snape Resigns
      Beiersdorf Shares Progress of Its Sustainability Agenda
      Estée Lauder Announces Second Edition of Beauty&You Brand Incubator Program
      Happi

      Latest Breaking News From Happi

      FDA Sends Warning Letter To Maker of Mr. Lulu Sunscreen Drops
      Enhanced Sustainable Nivea Sun and Lip Care Products
      Lysol’s New Mobile Science Center Will Visit Youth Sporting Events to Educate Families on Good Laundry Habits
      Ink World

      Latest Breaking News From Ink World

      SICPA Inaugurates Its unlimitrust Campus
      Siegwerk’s Center of Excellence in France Receives Facelift
      Epson announces MakeTheSwitch Campaign
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Gallus to celebrate 100 years, opening new Gallus Experience Center
      Mark Andy holds successful Low Migration Workshop
      Ryback & Ryback Consulting launches Machinery division
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Terra Baby Diapers, Wipes Launch in U.S. and Canada
      The Honest Company to Exit Europe, Asia
      TechnoPlants to Exhibit at ITMA
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Osso VR Launches Virtual Reality Training Program
      Catalyst OrthoScience Names Mark Quick as CFO
      European Regulators Approve Amber Implants' VCFix Spinal System Study
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Sensormatic Unveils Sensormatic Synergy Media Display
      ams OSRAM Receives the German Innovation Award
      ASSA ABLOY Receives Clearance from Mexico for HHI Acquisition

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login